Myeloproliferative Neoplasms

Naval G. Daver, MD, discusses persisting gaps in the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes.

John O. Mascarenhas, MD, discusses the potential role of imetelstat in the treatment of patients with myelofibrosis.

Higher response rates were shown with second-line ropeginterferon alfa-2b compared with anagrelide in patients with high-risk essential thrombocythemia.

A preview of the hematologic oncology abstracts and presentations to watch at the 2025 ESMO Congress in Berlin.

Andrew Kuykendall, MD, discussed the advantages and limitations of using QOL- and symptom-related end points in myelofibrosis clinical research.

John Mascarenhas, MD, outlines the ongoing phase 3 IMpact-MF trial, evaluating imetelstat in relapsed/refractory myelofibrosis.

Treatment with pacritinib in a real-world clinical setting led to hemoglobin responses in 44% of patients with myelofibrosis and anemia.

Naseema Gangat, MBBS, discusses the JAK inhibitor ruxolitinib as the standard of care for the treatment of patients with myelofibrosis.

Andrew Kuykendall, MD, details the benefit of rusfertide regarding quality of life in patients with polycythemia vera compared with placebo.

Hematology experts highlight the MDS, lymphoma, and myeloma data they were most excited to see at the 2025 SOHO Annual Meeting.

Sanam Loghavi, MD, discusses standard-of-care frontline testing in myelodysplastic syndrome.

First-line venetoclax plus azacitidine did not improve overall survival vs placebo plus azacitidine in treatment-naive, higher-risk MDS.

In case you missed any, below is a recap of every OncLive On Air episode that aired in August 2025.

Rusfertide earned an FDA breakthrough designation for polycythemia vera based on findings from the phase 3 VERIFY study.

Marina Kremyanskaya, MD, PhD, discusses the investigation of divesiran in polycythemia vera.

The top 5 OncLive videos of the week cover insights in polycythemia vera, multiple myeloma, colorectal cancer, LBCL, and mantle cell lymphoma.

Marina Kremyanskaya, MD, PhD, discusses early-phase findings with divesiran in patients with polycythemia vera.

Naseema Gangat, MBBS, delves into the role of ruxolitinib as a standard of care for the treatment of patients with polycythemia vera and myelofibrosis.

Naseema Gangat, MBBS, discusses the potential use of ruxolitinib and ropeginterferon alfa-2b-njft to reduce JAK2 allele burden in polycythemia vera.

Vepdegestrant NDA under FDA review in ESR1-mutated breast cancer, Oncomine Dx Target Test gets greenlit as zongertinib companion diagnostic in NSCLC.

Johannes Schetelig, MD, discusses challenges with assessing haploidentical related vs mismatched unrelated donor transplantation in high-risk AML/ALL/MDS

The development of SGR-2921 in relapsed/refractory AML and higher-risk MDS was discontinued followed by 2 patient deaths.

Andrew Kuykendall, MD, outlines the limitations of current clinical end points and discusses the need for molecularly informed drug development in MPN.

Marina Kremyanskaya, MD, PhD, discusses safety and early efficacy findings with divesiran in polycythemia vera.